

Pharmacodynamic Evaluation of Rezafungin (CD101) against Neutropenic Mouse Invasive Candidiasis Model

Antimicrobial Agents and Chemotherapy

62,

DOI: [10.1128/aac.01572-18](https://doi.org/10.1128/aac.01572-18)

Citation Report

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | Antifungal Resistance: Specific Focus on Multidrug Resistance in <i>Candida auris</i> and Secondary Azole Resistance in <i>Aspergillus fumigatus</i> . <i>Journal of Fungi</i> (Basel, Switzerland), 2018, 4, 129. | 1.5 | 29 |
| 2 | Extended-Interval Dosing of Rezafungin against Azole-Resistant <i>Aspergillus fumigatus</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, . | 1.4 | 18 |
| 3 | Combined Antifungal Resistance and Biofilm Tolerance: the Global Threat of <i>Candida auris</i> . <i>MSphere</i> , 2019, 4, . | 1.3 | 87 |
| 4 | Global epidemiology of emerging <i>Candida auris</i> . <i>Current Opinion in Microbiology</i> , 2019, 52, 84-89. | 2.3 | 178 |
| 5 | Efficacy of Delayed Therapy with Fosmanogepix (APX001) in a Murine Model of <i>Candida auris</i> Invasive Candidiasis. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, . | 1.4 | 50 |
| 6 | Determination of Pharmacodynamic Target Exposures for Rezafungin against <i>Candida tropicalis</i> and <i>Candida dubliniensis</i> in the Neutropenic Mouse Disseminated Candidiasis Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, . | 1.4 | 16 |
| 7 | <i>Candida auris</i> and multidrug resistance: Defining the new normal. <i>Fungal Genetics and Biology</i> , 2019, 131, 103243. | 0.9 | 112 |
| 8 | Fungal Cell Wall: Emerging Antifungals and Drug Resistance. <i>Frontiers in Microbiology</i> , 2019, 10, 2573. | 1.5 | 114 |
| 9 | Rezafungin treatment in mouse models of invasive candidiasis and aspergillosis: Insights on the PK/PD pharmacometrics of rezafungin efficacy. <i>Pharmacology Research and Perspectives</i> , 2019, 7, e00546. | 1.1 | 33 |
| 10 | The Fungal Cyp51-Specific Inhibitor VT-1598 Demonstrates <i>In Vitro</i> and <i>In Vivo</i> Activity against <i>Candida auris</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, . | 1.4 | 53 |
| 11 | Hope on the Horizon: Novel Fungal Treatments in Development. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa016. | 0.4 | 139 |
| 12 | Apc.LaeA and Apc.VeA of the velvet complex govern secondary metabolism and morphological development in the echinocandin-producing fungus <i>Aspergillus pachycristatus</i> . <i>Journal of Industrial Microbiology and Biotechnology</i> , 2020, 47, 155-168. | 1.4 | 14 |
| 13 | Echinocandins as Biotechnological Tools for Treating <i>Candida auris</i> Infections. <i>Journal of Fungi</i> (Basel, Switzerland), 2020, 6, 185. | 1.5 | 12 |
| 14 | Transcriptional and functional insights into the host immune response against the emerging fungal pathogen <i>Candida auris</i> . <i>Nature Microbiology</i> , 2020, 5, 1516-1531. | 5.9 | 75 |
| 15 | Efficacy of LAMB against Emerging Azole- and Multidrug-Resistant <i>Candida parapsilosis</i> Isolates in the <i>Galleria mellonella</i> Model. <i>Journal of Fungi</i> (Basel, Switzerland), 2020, 6, 377. | 1.5 | 14 |
| 16 | Rezafungin <i>In Vitro</i> Activity against Contemporary Nordic Clinical <i>Candida</i> Isolates and <i>Candida auris</i> Determined by the EUCAST Reference Method. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, . | 1.4 | 34 |
| 17 | Implications of Evolving and Emerging Pharmacokinetic-Pharmacodynamic Research for Triazoles and Echinocandins. <i>Current Fungal Infection Reports</i> , 2020, 14, 258-267. | 0.9 | 1 |
| 18 | Aspiring Antifungals: Review of Current Antifungal Pipeline Developments. <i>Journal of Fungi</i> (Basel,) Tj ETQq1 1 0.784314 rgBT /Overlook | 1.5 | 133 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Nine Things Genomics Can Tell Us About <i>Candida auris</i> . <i>Frontiers in Genetics</i> , 2020, 11, 351. | 1.1 | 47 |
| 20 | Echinocandins. , 2021, , 438-448. | | 0 |
| 21 | Rezafungin: a novel antifungal for the treatment of invasive candidiasis. <i>Future Microbiology</i> , 2021, 16, 27-36. | 1.0 | 31 |
| 22 | <i>Candida auris</i> : A New, Threatening Yeast. , 2021, , 544-555. | | 0 |
| 23 | Modelâ€informed Drug Development for Antiâ€infectives: State of the Art and Future. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 867-891. | 2.3 | 41 |
| 24 | Promising Drug Candidates and New Strategies for Fighting against the Emerging Superbug <i>Candida auris</i> . <i>Microorganisms</i> , 2021, 9, 634. | 1.6 | 29 |
| 25 | Comparison of In Vitro Killing Activity of Rezafungin, Anidulafungin, Caspofungin, and Micafungin against Four <i>Candida auris</i> Clades in RPMI-1640 in the Absence and Presence of Human Serum. <i>Microorganisms</i> , 2021, 9, 863. | 1.6 | 22 |
| 26 | New weapons to fight a new enemy: A systematic review of drug combinations against the drugâ€resistant fungus <i>Candida auris</i> . <i>Mycoses</i> , 2021, 64, 1308-1316. | 1.8 | 15 |
| 28 | Ibrexafungerp Demonstrates <i>In Vitro</i> Activity against Fluconazole-Resistant <i>Candida auris</i> and <i>In Vivo</i> Efficacy with Delayed Initiation of Therapy in an Experimental Model of Invasive Candidiasis. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, . | 1.4 | 27 |
| 29 | How urgent is the need for new antifungals?. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 1857-1870. | 0.9 | 18 |
| 31 | Antifungal Pipeline. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 732223. | 1.8 | 24 |
| 32 | New and Promising Chemotherapeutics for Emerging Infections Involving Drug-resistant Non-albicans <i>Candida</i> Species. <i>Current Topics in Medicinal Chemistry</i> , 2019, 19, 2527-2553. | 1.0 | 20 |
| 33 | Review of the Novel Echinocandin Antifungal Rezafungin: Animal Studies and Clinical Data. <i>Journal of Fungi (Basel, Switzerland)</i> , 2020, 6, 192. | 1.5 | 25 |
| 34 | Therapeutic Drug Monitoring of the Echinocandin Antifungal Agents: Is There a Role in Clinical Practice? A Position Statement of the Anti-Infective Drugs Committee of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. <i>Therapeutic Drug Monitoring</i> , 2022, 44, 198-214. | 1.0 | 14 |
| 35 | Optimization of Dosage Regimen of Rezafungin against <i>Candida</i> spp. Based on Pharmacokinetic/Pharmacodynamic Analysis. <i>Pharmacology & Pharmacy</i> , 2020, 11, 79-84. | 0.2 | 0 |
| 36 | Current scenario of the search for new antifungal agents to treat <i>Candida auris</i> infections: An integrative review. <i>Journal De Mycologie Medicale</i> , 2022, 32, 101232. | 0.7 | 4 |
| 37 | Emerging and future strategies in the management of recalcitrant <i>Candida auris</i> . <i>Medical Mycology</i> , 2022, 60, . | 0.3 | 22 |
| 38 | Overview about <i>Candida auris</i> : What's up 12 years after its first description?. <i>Journal De Mycologie Medicale</i> , 2022, 32, 101248. | 0.7 | 16 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 39 | Drug Resistance and Novel Therapeutic Approaches in Invasive Candidiasis. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 759408. | 1.8 | 31 |
| 40 | Postantifungal Effect of Antifungal Drugs against <i>Candida</i> : What Do We Know and How Can We Apply This Knowledge in the Clinical Setting?. <i>Journal of Fungi (Basel, Switzerland)</i> , 2022, 8, 727. | 1.5 | 3 |
| 41 | Small molecules for combating multidrug-resistant superbug <i>Candida auris</i> infections. <i>Acta Pharmaceutica Sinica B</i> , 2022, 12, 4056-4074. | 5.7 | 9 |
| 42 | Pharmacodynamics, Mechanisms of Action and Resistance, and Spectrum of Activity of New Antifungal Agents. <i>Journal of Fungi (Basel, Switzerland)</i> , 2022, 8, 857. | 1.5 | 25 |
| 43 | Development and research progress of anti-drug resistant fungal drugs. <i>Journal of Infection and Public Health</i> , 2022, 15, 986-1000. | 1.9 | 17 |
| 44 | Recent Antifungal Pipeline Developments against <i>Candida auris</i> : A Systematic Review. <i>Journal of Fungi (Basel, Switzerland)</i> , 2022, 8, 1144. | 1.5 | 8 |
| 45 | Assessment of Antifungal Pharmacodynamics. <i>Journal of Fungi (Basel, Switzerland)</i> , 2023, 9, 192. | 1.5 | 1 |
| 46 | Novel Therapeutic Approaches to Invasive Candidiasis: Considerations for the Clinician. <i>Infection and Drug Resistance</i> , 0, Volume 16, 1087-1097. | 1.1 | 10 |
| 47 | Challenges in the diagnosis and treatment of candidemia due to multidrug-resistant <i>Candida auris</i> . <i>Frontiers in Fungal Biology</i> , 0, 4, . | 0.9 | 2 |
| 48 | <i>Candida Auris</i>: What do We Know about the Most Enigmatic Pathogen of the 21st Century?. <i>Postepy Mikrobiologii</i> , 2023, 62, 27-46. | 0.1 | 0 |
| 52 | The Role of Novel Antifungals in the Management of Candidiasis: A Clinical Perspective. <i>Mycopathologia</i> , 2023, 188, 937-948. | 1.3 | 4 |